This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
LOS ANGELES–(BUSINESS WIRE)–Jan 9, 2020– Oasis Intelligence officially launched today, offering brand marketers in the cannabis and hemp industry, as well as related sectors, a much needed tool: unprecedented access to consumer insights at scale. Simple access to cannabis is the initial driver of sales.
Note: while we don’t believe that anyone in Congress has proposed it yet, the Federal government could legalize cannabis for medical use [and perhaps for recreational use] and preempt many of the state laws. We have written a set of seven whitepapers that are available to the public to review. for the same information.
What will unrestricted access to Medicinal Cannabis look like in Australia? A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals Right now in Australia, access to Cannabis-based treatments is heavily restricted. kg of CBD and 163.7
The rationale for the is consumer safety – which seems like a legitimate concern given that recreational use cannabis producers were previously not required to test for pesticides at all. Processors in particular, says the whitepaper cited above “who extract cannabis oil from plant material hold the greatest risk.”
The Board’s consumer safety concern is indeed a legitimate one as recreational use cannabis producers were previously not required to test for pesticides at all. a WA licensed cannabis testing laboratory, in a whitepaper released in February, the issue of pesticide contamination in cannabis products in the state is serious.
This whitepaper offers a primer to the complex and confusing global cannabis industry as it stands today. Colorado has legalized both recreational and medical use of cannabis. Outsiders are coming in thinking that we’ll be passing legal recreational marijuana shortly and are willing to invest.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content